Review article: monitoring of immunomodulators in inflammatory bowel disease
- PMID: 15709982
- DOI: 10.1111/j.1365-2036.2005.02343.x
Review article: monitoring of immunomodulators in inflammatory bowel disease
Abstract
The armamentarium of medications for the treatment of inflammatory bowel disease is growing and becoming more complicated to use. Immunomodulators are a class of medications that have found a niche for the treatment of Crohn's disease and ulcerative colitis. Because of the mounting supporting evidence for efficacy, the most commonly-used immunomodulators are azathioprine, mercaptopurine, methotrexate and ciclosporin. These medications are being used more often due to their steroid-sparing and potentially surgery-sparing effects. Immunomodulators are also known for a significant side-effect profile and require careful monitoring. This review provides the latest information for clinicians on efficacy, side-effects, dosing and monitoring of these medications for treatment of inflammatory bowel disease.
Similar articles
-
Review article: practical management of inflammatory bowel disease patients taking immunomodulators.Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16. doi: 10.1111/j.1365-2036.2005.02520.x. Aliment Pharmacol Ther. 2005. PMID: 15963074 Review.
-
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
-
General principles of medical therapy of inflammatory bowel disease.Gastroenterol Clin North Am. 2004 Jun;33(2):191-208, viii. doi: 10.1016/j.gtc.2004.02.003. Gastroenterol Clin North Am. 2004. PMID: 15177534 Review.
-
Immunosuppressive drugs in the treatment of inflammatory bowel disease.Semin Gastrointest Dis. 1998 Jan;9(1):2-9. Semin Gastrointest Dis. 1998. PMID: 9547850 Review.
-
Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.Am J Gastroenterol. 1993 Jan;88(1):44-8. Am J Gastroenterol. 1993. PMID: 8420272
Cited by
-
Advances in therapeutic approaches to ulcerative colitis and Crohn's disease.Curr Gastroenterol Rep. 2005 Dec;7(6):475-84. doi: 10.1007/s11894-005-0079-9. Curr Gastroenterol Rep. 2005. PMID: 16313878 Review.
-
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.Clin Pharmacokinet. 2019 Jan;58(1):15-37. doi: 10.1007/s40262-018-0676-z. Clin Pharmacokinet. 2019. PMID: 29752633 Free PMC article. Review.
-
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.World J Gastroenterol. 2011 Aug 14;17(30):3467-78. doi: 10.3748/wjg.v17.i30.3467. World J Gastroenterol. 2011. PMID: 21941413 Free PMC article.
-
Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis.Int J Nanomedicine. 2018 Feb 28;13:1225-1240. doi: 10.2147/IJN.S157566. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29535519 Free PMC article.
-
Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A.Pharmaceutics. 2022 Dec 15;14(12):2811. doi: 10.3390/pharmaceutics14122811. Pharmaceutics. 2022. PMID: 36559305 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources